Clinical trial NCT02254538: A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers
Official title: A Double-blind (at Each Dose Level), Randomised, Placebo-controlled Single Increasing Dose Safety, Tolerability and Preliminary Pharmacokinetics Study in Healthy Male Volunteers After Oral Administration of BILR 355 BS Solved in PEG 400 (Dosage: 1 - 200 mg)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-10-02
Enrollment: 54
Sex: MALE
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Assessment of safety, tolerability and preliminary pharmacokinetics in healthy male volunteers after oral administration of BILR 355 BS


Eligibility criteria: Inclusion Criteria:

All participants in the study should be healthy males, ranging from 21 to 50 years of age and their body mass index (BMI) be within 18.5 to 29.9 kg/m2 (BMI calculation: weight in kilograms divided by the square of height in meters).

In accordance with Good clinical practice (GCP) and the local legislation all volunteers will have given their written informed consent prior to admission to the study

Exclusion Criteria:

* Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
* Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
* History of orthostatic hypotension, fainting spells or blackouts
* Chronic or relevant acute infections
* History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
* Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study
* Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the study or during the study
* Participation in another trial with an investigational drug (≤ two months prior to administration or during the trial)
* Smoker (\> 10 cigarettes or \> 3 cigars of \> 3 pipes/day)
* Inability to refrain from smoking on trial days
* Alcohol abuse (\> 60 g/day)
* Drug abuse
* Blood donation (≥ 100 mL within four weeks prior to administration or during the trial)
* Any laboratory value outside the clinically accepted reference range
* Excessive physical activities within the last week before the trial or during the trial

Following exclusion criteria are of special interest for this study:

- Erythema, exanthema and comparable skin alterations

Primary outcomes:
measure: Number of participants with clinically significant changes in vital functions
timeFrame: Up to 10 days after drug administration
measure: Number of participants with abnormal findings in ECG (electrocardiogram)
timeFrame: Up to 10 days after drug administration
measure: Number of participants with abnormal findings in skin inspections
timeFrame: Up to 10 days after drug administration
measure: Number of participants with abnormal neurological finding
timeFrame: Up to 10 days after drug administration
measure: Number of participants with abnormal changes in laboratory parameters
timeFrame: Up to 10 days after drug administration
measure: Number of participants with positive faecal occult blood testing
timeFrame: Up to 10 days after drug administration
measure: Number of participants with adverse events
timeFrame: Up to 10 days after drug administration
Secondary outcomes:
measure: Maximum plasma concentration (Cmax)
timeFrame: Up to 144 hours after drug administration
measure: Time to attain maximum plasma concentration (tmax)
timeFrame: Up to 144 hours after drug administration
measure: Area under the concentration-time curve of the analyte in plasma from zero time to infinity (AUC0-∞)
timeFrame: Up to 144 hours after drug administration
measure: Terminal half life (t½)
timeFrame: Up to 144 hours after drug administration
measure: Apparent clearance of the analyte in plasma following extravascular administration (CL/F)
timeFrame: Up to 144 hours after drug administration
measure: Total mean residence time (MRTtot)
timeFrame: Up to 144 hours after drug administration
measure: Apparent volume of distribution during the terminal elimination phase (Vz/F)
timeFrame: Up to 144 hours after drug administration
measure: Renal clearance of the analyte (CLR)
timeFrame: Up to 72 hours after drug administration
measure: Amount of drug excreted in the urine (Ae)
timeFrame: Up to 72 hours after drug administration
measure: Area under the concentration-time curve of the analyte in plasma from zero time to the time of the last quantifiable drug concentration (AUC0-tz)
timeFrame: Up to 144 hours after drug administration
Other outcomes:
Locations:
Study officials:
References: